The FDA approval is specifically for the treatment of patients with BRCA-mutated HER2-negative high-risk early breast cancer who have already received chemotherapy treatment either before or after surgery.
As the most diagnosed cancer worldwide, an estimated 2.3 million patients were diagnosed with breast cancer in 2020. In the US, almost 91% of all breast cancer patients are diagnosed at an early stage of disease, with BRCA mutations found in approximately 5-10% of patients.
